Scarica l'app Stockscreener
131.60
0.72%
-0.96
Dopo l'orario di chiusura:
131.20
-0.40
-0.30%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$132.56
Aprire:
$130.81
Volume 24 ore:
706.65K
Relative Volume:
0.63
Capitalizzazione di mercato:
$13.21B
Reddito:
$2.86B
Utile/perdita netta:
$478.60M
Rapporto P/E:
28.19
EPS:
4.6676
Flusso di cassa netto:
$748.70M
1 W Prestazione:
-0.62%
1M Prestazione:
-0.59%
6M Prestazione:
-3.76%
1 anno Prestazione:
+21.50%
Intervallo 1D:
$130.00
$133.75
Intervallo di 1 settimana:
$128.02
$133.99
Portata 52W:
$84.23
$160.18
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Nome
Neurocrine Biosciences Inc
Settore
Telefono
(858) 617-7600
Indirizzo
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
131.60 | 13.21B | 2.86B | 478.60M | 748.70M | 4.6676 |
TAK
Takeda Pharmaceutical Co Adr
|
18.74 | 59.20B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
117.94 | 49.79B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.93 | 44.27B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.08 | 35.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
564.81 | 24.75B | 3.18B | 1.33B | 1.04B | 27.90 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2026-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-21 | Iniziato | Citigroup | Buy |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-10 | Iniziato | Goldman | Buy |
| 2025-04-15 | Aggiornamento | Needham | Hold → Buy |
| 2025-04-14 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-08-29 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Ripresa | Citigroup | Neutral |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Reiterato | Mizuho | Neutral |
| 2023-07-24 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-30 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-09-26 | Iniziato | Wells Fargo | Equal Weight |
| 2022-06-06 | Ripresa | Jefferies | Buy |
| 2022-03-03 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-01-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Iniziato | BMO Capital Markets | Underperform |
| 2021-11-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Ripresa | Needham | Hold |
| 2021-08-06 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-05-06 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Iniziato | Raymond James | Outperform |
| 2020-09-30 | Iniziato | The Benchmark Company | Hold |
| 2020-08-04 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Downgrade | Goldman | Buy → Neutral |
| 2020-06-09 | Iniziato | Wedbush | Outperform |
| 2020-03-06 | Iniziato | Citigroup | Buy |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-24 | Iniziato | William Blair | Outperform |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2020-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-13 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-07-16 | Iniziato | Oppenheimer | Outperform |
| 2019-06-05 | Iniziato | Guggenheim | Neutral |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-02-06 | Reiterato | BofA/Merrill | Buy |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Iniziato | Goldman | Buy |
| 2018-11-21 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie
Nisa Investment Advisors Reduces Neurocrine Biosciences Stake - National Today
Nisa Investment Advisors LLC Sells 21,945 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Risks Report: Is Neurocrine Biosciences Inc a turnaround storyMarket Weekly Review & High Win Rate Trade Tips - baoquankhu1.vn
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) Q4 2025 earnings call transcript - MSN
A Look At Neurocrine Biosciences (NBIX) Valuation After New INGREZZA Data In Older Tardive Dyskinesia Patients - Sahm
Should You be Optimistic on Neurocrine Biosciences (NBIX)? - MSN
Neurocrine Biosciences Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
NBIX Financials: Revenue Breakdown, Margins & Competitor Comparison - intellectia.ai
8,437 Shares in Neurocrine Biosciences, Inc. $NBIX Acquired by Nilsine Partners LLC - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Allspring Global Investments Holdings LLC - MarketBeat
Neurocrine Biosciences, Inc. (NBIX) Stock forecasts - Yahoo Finance UK
What Neurocrine Biosciences (NBIX)'s New Senior TD Data and Guidelines Could Mean For Shareholders - Sahm
NBIX Technical Analysis & Stock Price Forecast - intellectia.ai
Neurocrine Biosciences Inc (NBIX) Shares Up 3.15% on Mar 31 - GuruFocus
Responsive Playbooks and the NBIX Inflection - Stock Traders Daily
Neurocrine Biosciences Inc (NBIX) Shares Down 3.14% on Mar 30 - GuruFocus
Needham bullish on Neurocrine Biosciences, Inc. (NBIX) pipeline amid 2026 growth expectations for Crenessity and Ingrezza - MSN
NBIX SEC FilingsNeurocrine Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Neurocrine Biosciences Stock: A Leader in Neurological and Endocrine Therapies with Strong US Market - AD HOC NEWS
Wealth Enhancement Advisory Services LLC Boosts Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Free cash flow per share of Neurocrine Biosciences, Inc. – DUS:NB3 - TradingView
SG Americas Securities LLC Buys 119,339 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Nordea Investment Boosts Stake in Neurocrine Biosciences - National Today
Nordea Investment Management AB Increases Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Assenagon Asset Management S.A. Has $11.35 Million Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
[SCHEDULE 13G/A] NEUROCRINE BIOSCIENCES INC Amended Passive Investment Disclosure - Stock Titan
Neurocrine (NASDAQ:NBIX) Expands Clinical Strategy As Nasdaq Futures Shift - Kalkine Media
Tudor Investment Corp ET AL Buys 23,893 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Is Geriatric-Focused INGREZZA Data Quietly Reframing Neurocrine Biosciences' Neurology Leadership Narrative (NBIX)? - Yahoo Finance
Neurocrine Biosciences Updates Tardive Dyskinesia Care And Valuation Story - simplywall.st
Neurocrine presents tardive dyskinesia treatment guidance for elderly - StreetInsider
Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings - PR Newswire
Neurocrine Biosciences Inc (NBIX) Shares Up 3.53% on Mar 25 - GuruFocus
Earnings Miss: Why is Neurocrine Biosciences Inc stock going upProfit Target & Consistent Growth Equity Picks - baoquankhu1.vn
Shorts Report: Does Neurocrine Biosciences Inc have pricing powerTrend Reversal & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
New long-term care guidance calls for quarterly tardive dyskinesia screening - Stock Titan
Neurocrine Biosciences Inc. (NASDAQ:NBIX) Presents a Strong Growth and Technical Setup - ChartMill
Truist lowers Neurocrine Biosciences, Inc.’s (NBIX) PT following 2026 outlook update - MSN
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential - The Motley Fool
Neurocrine Biosciences, Inc.Common Stock (NQ: NBIX - FinancialContent
CIBC Private Wealth Group Boosts Neurocrine Biosciences Stock Holdings - National Today
CIBC Private Wealth Group LLC Grows Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Assessing Neurocrine Biosciences (NBIX) Valuation As Shares Soften Despite Growing Revenue And Net Income - Sahm
Block Trades: Can Neurocrine Biosciences Inc be recession proofProfit Target & Long Hold Capital Preservation Plans - baoquankhu1.vn
Hedge Fund Bets: Can Neurocrine Biosciences Inc maintain its current growth rateWall Street Watch & Safe Entry Trade Signal Reports - baoquankhu1.vn
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Hudson Bay Capital Management LP - MarketBeat
Neurocrine Biosciences Inc Azioni (NBIX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):